Figure 4
Figure 4. B-cell immune function. (A) CD19+ cell subpopulations in patients treated with haploidentical HSCT and GT. Percentage range of each subpopulation (ie, naives IgD+CD27−, marginal zone IgD+CD27+, switched memory IgD−CD27+, and IgD−CD27− cells) is indicated. (B) IgM levels (g/L) on day 0 and at 2 years in haploidentical HSCT patients and GT patients. (C) IgA levels (g/L) on day 0 and at 2 years in haplo-identical HSCT patients and GT patients. Extremities of the whiskers boxes represent minimum and maximum values. Bottom and top of the box represent the first and third quartiles, respectively. The horizontal bar in the box represents the median value.

B-cell immune function. (A) CD19+ cell subpopulations in patients treated with haploidentical HSCT and GT. Percentage range of each subpopulation (ie, naives IgD+CD27, marginal zone IgD+CD27+, switched memory IgDCD27+, and IgDCD27 cells) is indicated. (B) IgM levels (g/L) on day 0 and at 2 years in haploidentical HSCT patients and GT patients. (C) IgA levels (g/L) on day 0 and at 2 years in haplo-identical HSCT patients and GT patients. Extremities of the whiskers boxes represent minimum and maximum values. Bottom and top of the box represent the first and third quartiles, respectively. The horizontal bar in the box represents the median value.

Close Modal

or Create an Account

Close Modal
Close Modal